KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eli Lilly (LLY) Income from Continuing Operations (2016 - 2026)

Eli Lilly filings provide 18 years of Income from Continuing Operations readings, the most recent being 7396000000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations rose 168.07% to 7396000000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 25276700000.0, a 127.59% increase, with the full-year FY2025 number at 20640000000.0, up 94.9% from a year prior.
  • Income from Continuing Operations hit 7396000000.0 in Q1 2026 for Eli Lilly, up from 6637700000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 7396000000.0 in Q1 2026 to a low of 57400000.0 in Q3 2023.
  • Median Income from Continuing Operations over the past 5 years was 2189300000.0 (2023), compared with a mean of 2947676470.59.
  • Biggest five-year swings in Income from Continuing Operations: crashed 103.95% in 2023 and later skyrocketed 1790.42% in 2024.
  • Eli Lilly's Income from Continuing Operations stood at 1937700000.0 in 2022, then increased by 12.98% to 2189300000.0 in 2023, then skyrocketed by 101.43% to 4409800000.0 in 2024, then soared by 50.52% to 6637700000.0 in 2025, then grew by 11.42% to 7396000000.0 in 2026.
  • The last three reported values for Income from Continuing Operations were 7396000000.0 (Q1 2026), 6637700000.0 (Q4 2025), and 5582500000.0 (Q3 2025) per Business Quant data.